Join Now

Category Archives: BioUtah News

Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility

By admin | Published December 12, 2024

SALT LAKE CITY, Dec. 10, 2024 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt. Ltd.’s oligonucleotide synthesis facility will take place December 11, 2024, in Ranoli, India. In support of the “Make […]

| Comments Off on Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility

Halia Therapeutics Announces Positive Topline Data and Advances to Second Stage of Phase 2 Clinical Trial for HT-6184 in Patients with Low-Risk Myelodysplastic Syndromes (LR-MDS)

By admin | Published December 12, 2024

LEHI, Utah, Dec. 10, 2024 /PRNewswire/ — Halia Therapeutics, a biopharmaceutical company at the forefront of developing treatments for chronic inflammation and related disorders, announced today promising topline data resulting in the advancement to the second stage of its Phase 2 clinical trial evaluating HT-6184, a first-in-class allosteric NEK7/NLRP3 inflammasome inhibitor given orally, in patients with lower-risk […]

| Comments Off on Halia Therapeutics Announces Positive Topline Data and Advances to Second Stage of Phase 2 Clinical Trial for HT-6184 in Patients with Low-Risk Myelodysplastic Syndromes (LR-MDS)

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

By Natalie Themm | Published December 12, 2024

Recursion reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors.

| Tagged | Comments Off on Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

CancerVax Targets Hard to Treat Pancreatic Cancer

By Natalie Themm | Published December 12, 2024

With limited options available to treat Pancreatic Ductal Adenocarcinoma (PDAC), the Company’s Universal Cancer Treatment Platform may provide hope for patients and doctors

| Tagged | Comments Off on CancerVax Targets Hard to Treat Pancreatic Cancer

BIOFIRE® FILMARRAY® Tropical Fever Panel, a syndromic PCR test targeting causes of tropical fever infections, receives U.S. FDA Special 510(k) clearance

By Natalie Themm | Published December 12, 2024

BIOFIRE® FILMARRAY® Tropical Fever Panel, a syndromic PCR test targeting causes of tropical fever infections, receives U.S. FDA Special 510(k) clearance

| Tagged , | Comments Off on BIOFIRE® FILMARRAY® Tropical Fever Panel, a syndromic PCR test targeting causes of tropical fever infections, receives U.S. FDA Special 510(k) clearance

Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines

By Natalie Themm | Published December 12, 2024

Prolaris, MyRisk, and Precise Tumor Testing Validated Across Cancer Stages, Elevating Company’s Comprehensive Patient-Centric Solutions

| Tagged | Comments Off on Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium

By Natalie Themm | Published December 12, 2024

Presentations include analytical validation of Myriad’s high-definition tumor informed MRD assay for breast cancer and its Breast Cancer Risk Assessment Tool MyRisk® with RiskScore®

| Tagged | Comments Off on Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium

PhotoPharmics to Present Patient Interest Findings from Groundbreaking Remote Parkinson’s Trial at PSG Annual Meeting

By admin | Published December 5, 2024

Presentation to Highlight Feasibility and Interest in Decentralized Home-Based Phase 3 Trial Salt Lake City, Utah — December 5, 2024 — PhotoPharmics, a pioneer in non-invasive phototherapy for neurological disorders, today announced it will present a poster titled “An Entirely Remote, Home-based Phase 3 Clinical Trial of a Specialized Light Therapy Device for Parkinson’s Disease […]

| Comments Off on PhotoPharmics to Present Patient Interest Findings from Groundbreaking Remote Parkinson’s Trial at PSG Annual Meeting

Fluidx Medical Begins Multinational Trial of GPX Embolic Device

By admin | Published December 5, 2024

November 27, 2024—Fluidx Medical Technology, Inc. announced that the first patient has been treated in the prospective, multinational, clinical trial of the company’s GPX embolic device. The device was successfully used in a portal vein embolization procedure in preparation for hepatic resection. According to the company, the safety and effectiveness trial includes leading medical centers […]

| Comments Off on Fluidx Medical Begins Multinational Trial of GPX Embolic Device

Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease

By admin | Published December 5, 2024

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich repeat kinase 2 (LRRK2) inhibitor BIIB122 (DNL151) in participants with LRRK2-associated Parkinson’s disease (LRRK2-PD). LRRK2 inhibition is a potential therapeutic approach that […]

| Comments Off on Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease

Canary Speech Named to the 2024 CB Insights’ List of the 50 Most Innovative Digital Health Startups

By Natalie Themm | Published December 5, 2024

Canary Speech recognized for achievements in non-invasive diagnostics in the most promising private digital health companies across the globe.

| Tagged | Comments Off on Canary Speech Named to the 2024 CB Insights’ List of the 50 Most Innovative Digital Health Startups

Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma

By Natalie Themm | Published December 5, 2024

First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesized

| Tagged | Comments Off on Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma

A Special Thanks To Our Legacy and Platinum Elite Members